RESEARCH TRIANGLE PARK, N.C. , June 26, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology,
RESEARCH TRIANGLE PARK, N.C. , June 05, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today provided an update on the Phase 3 INSPIRE trial and development of LIQ861 for the treatment of pulmonary arterial
RESEARCH TRIANGLE PARK, N.C. , April 08, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced that the
RESEARCH TRIANGLE PARK, N.C. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that
To include highlights of the safety and tolerability of LIQ861 at two months of treatment in the INSPIRE Phase 3 Trial RESEARCH TRIANGLE PARK, N.C. , May 14, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today
RESEARCH TRIANGLE PARK, N.C. , May 22, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz , M.D., as Chief Financial Officer (CFO). Dr.
RESEARCH TRIANGLE PARK, N.C. , May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced the
RESEARCH TRIANGLE PARK, N.C. , April 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that it has
